Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
CASE REPORTS
Membranous Nephropathy Associated with the Relatively Selective Cyclooxygenase-2 Inhibitor, Etodolac, in a Patient with Early Rheumatoid Arthritis
Toshiro SugimotoMasahiro AoyamaKatsuhisa KikuchiMasayoshi SakaguchiNaoko DejiTakashi UzuYoshihiko NishioAtsunori Kashiwagi
Author information
JOURNALS OPEN ACCESS

2007 Volume 46 Issue 13 Pages 1055-1058

Details
Abstract

Renal dysfunction and urinary abnormalities, which are usually related to drug toxicity, secondary amyloidosis, or those which overlap with other autoimmune conditions, are frequently observed in patients with rheumatoid arthritis. This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac. The present case suggests that any kind of non-steroidal anti-inflammatory drug can cause membranous nephropathy; thus, physicians should be aware of this renal toxicity when prescribing these drugs.

Information related to the author
© 2007 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top